Vistagen Therapeutics (VTGN) Profit After Tax (2017 - 2025)
Historic Profit After Tax for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$18.9 million.
- Vistagen Therapeutics' Profit After Tax fell 3414.01% to -$18.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$67.0 million, marking a year-over-year decrease of 4173.43%. This contributed to the annual value of -$51.4 million for FY2025, which is 7511.75% down from last year.
- Per Vistagen Therapeutics' latest filing, its Profit After Tax stood at -$18.9 million for Q4 2025, which was down 3414.01% from -$19.4 million recorded in Q3 2025.
- In the past 5 years, Vistagen Therapeutics' Profit After Tax ranged from a high of -$6.2 million in Q1 2021 and a low of -$19.8 million during Q2 2022
- Over the past 5 years, Vistagen Therapeutics' median Profit After Tax value was -$12.5 million (recorded in 2021), while the average stood at -$12.4 million.
- In the last 5 years, Vistagen Therapeutics' Profit After Tax plummeted by 28798.59% in 2021 and then surged by 6509.46% in 2023.
- Over the past 5 years, Vistagen Therapeutics' Profit After Tax (Quarter) stood at -$10.5 million in 2021, then rose by 7.34% to -$9.8 million in 2022, then surged by 34.95% to -$6.4 million in 2023, then crashed by 121.87% to -$14.1 million in 2024, then tumbled by 34.14% to -$18.9 million in 2025.
- Its last three reported values are -$18.9 million in Q4 2025, -$19.4 million for Q3 2025, and -$15.1 million during Q2 2025.